ArticleBritish journal of cancer2001
TP53 mutations, amplification of P63 and expression of cell cycle proteins in squamous cell carcinoma of the oesophagus from a low incidence area in Western Europe.
Article in British journal of cancer, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 44 citations in OpenAlex.
- Article
- Personalized and targeted therapy of esophageal squamous cell carcinoma: an update.Annals of the New York Academy of Sciences · 2016Review
- The potential of molecular markers to improve interventions through the natural history of oesophageal squamous cell carcinoma.Bioscience reports · 2013Review
- p63 regulates cell proliferation and cell cycle progression‑associated genes in stromal cells of giant cell tumor of the bone.International journal of oncology · 2013Article
- TP63 P2 promoter functional analysis identifies β-catenin as a key regulator of ΔNp63 expression.Oncogene · 2011Article
- Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression.The American journal of pathology · 2011Article
- Extremely high Tp53 mutation load in esophageal squamous cell carcinoma in Golestan Province, Iran.PloS one · 2011Article
- Adenovirus expressing p27kip1 suppresses growth of established esophageal carcinoma xenografts.World journal of gastroenterology · 2005Article
- Inhibitory effect of ubiquitin-proteasome pathway on proliferation of esophageal carcinoma cells.World journal of gastroenterology · 2004Article
- Inhibition of adenovirus-mediated p27kip1 gene on growth of esophageal carcinoma cell strain.World journal of gastroenterology · 2003Article
- Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date.Drug safety · 2003Review
- Distinct pattern of TP53 mutations in squamous cell carcinoma of the esophagus in Iran.Oncogene · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Europe, high incidence rates of oesophageal squamous cell carcinoma (SCCE) are observed in western France (Normandy and Brittany) and in north-eastern Italy. Analysis of TP53 mutations in tumours from these regions has shown a high prevalence of mutations at A:T basepairs that may result from DNA damage caused by specific mutagens. However, the spectrum of TP53 mutations in regions of low incidence is unknown. We report here TP53 mutation analysis in 33 SCCE collected in Lyon, an area of low incidence. These tumours were also examined for MDM2 and P63 amplification, and for expression of p16(INK4a/CDKN2a), cyclin E, p27(Kipl)and Cox2. TP53 mutations were detected in 36% of the cases (12/33). In contrast with regions of high incidence, the mutation spectrum did not show a high prevalence of mutations at A:T base pairs. P63 was amplified in 5/32 cases tested (15.5%). No amplification of MDM2 was found. Expression studies revealed frequent loss of p16(INK4a/CDKN2a)(46%) and p27(Kipl)(25%) expression, and frequent overexpression of Cyclin E (70%) and Cox2 (42%). Overall, these results indicate that in Europe, SCCE from areas of high and low incidence present a similar pattern of molecular alterations but differ by the type of TP53 mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.